The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial (2013)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- Subjects: MEDICAMENTO; ANTICOAGULANTES; SÍNDROME CORONARIANA AGUDA
- Language: Inglês
- Imprenta:
- Source:
- Título: Circulation
- ISSN: 0009-7322
- Volume/Número/Paginação/Ano: v. 128, n. 22, abst. 11382, 2013
- Conference titles: American Heart Associations of the Scientific Sessions and Resuscitation Science Symposium
-
ABNT
O'DONOGHUE, Michelle L. et al. The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial. Circulation. Dallas: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://circ.ahajournals.org/cgi/content/meeting_abstract/128/22_MeetingAbstracts/A11382?sid=6b0e288c-1566-44fe-b492-e72d89bd73f4. Acesso em: 10 jan. 2026. , 2013 -
APA
O'Donoghue, M. L., Mega, J. L., Braunwald, E., Nicolau, J. C., Bhatt, D. L., Murphy, S. A., & Gibson, C. M. (2013). The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial. Circulation. Dallas: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://circ.ahajournals.org/cgi/content/meeting_abstract/128/22_MeetingAbstracts/A11382?sid=6b0e288c-1566-44fe-b492-e72d89bd73f4 -
NLM
O'Donoghue ML, Mega JL, Braunwald E, Nicolau JC, Bhatt DL, Murphy SA, Gibson CM. The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial [Internet]. Circulation. 2013 ; 128( 22):[citado 2026 jan. 10 ] Available from: http://circ.ahajournals.org/cgi/content/meeting_abstract/128/22_MeetingAbstracts/A11382?sid=6b0e288c-1566-44fe-b492-e72d89bd73f4 -
Vancouver
O'Donoghue ML, Mega JL, Braunwald E, Nicolau JC, Bhatt DL, Murphy SA, Gibson CM. The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial [Internet]. Circulation. 2013 ; 128( 22):[citado 2026 jan. 10 ] Available from: http://circ.ahajournals.org/cgi/content/meeting_abstract/128/22_MeetingAbstracts/A11382?sid=6b0e288c-1566-44fe-b492-e72d89bd73f4 - Oclusão de comunicação interventricular pós-infarto com prótese percutânea CERA
- Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial
- Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease
- Timing, Profile, and Predictors of Spontaneous Myocardial Infarction Following a Non-ST-Segment Elevation Acute Coronary Syndrome Event: Insights From the TRILOGY-ACS Trial
- Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
- Reduction in aubtypes and sizes of myocardial infarction with ticagrelor in PEGASUS-TIMI 54
- Left ventricular hypertrophy and QTc dispersion are predictors of long-term mortality in subjects with type 2 diabetes
- P2Y12 inhibitor switching in response to routine notification of CYP2C19 clopidogrel metabolizer status following acute coronary syndromes
- Extent of coronary and myocardial disease and benefit from surgical revascularization in LV dysfunction
- Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
